Literature DB >> 15070992

Characterization of multidrug-resistant typhoid outbreaks in Kenya.

Samuel Kariuki1, Gunturu Revathi, Jane Muyodi, Joyce Mwituria, Agnes Munyalo, Sajjad Mirza, C Anthony Hart.   

Abstract

We characterized by antibiotic susceptibility, plasmid analysis, incompatibility grouping, and pulsed-field gel electrophoresis (PFGE) of XbaI- and SpeI-digested DNA 102 Salmonella enterica serovar Typhi (serovar Typhi) isolated from recent outbreaks of typhoid in three different parts of Kenya. Only 13.7% were fully susceptible, whereas another 82.4% were resistant to each of the five commonly available drugs: ampicillin, chloramphenicol, and tetracycline (MICs of >256 microg/ml); streptomycin (MIC, >1,024 microg/ml); and cotrimoxazole (MIC of >32 microg/ml). Resistance to these antibiotics was encoded on a 110-kb self-transferable plasmid of IncHI1 incompatibility group. The MICs of nalidixic acid (MIC, 8 to 16 micro g/ml) and ciprofloxacin (MIC of 0.25 to 0.38 micro g/ml) for 41.7% of the 102 serovar Typhi isolates were 5- and 10-fold higher, respectively, than for sensitive strains. Amplification by PCR and sequencing of the genes coding for gyrase (gyrA and gyrB) and topoisomerase IV (parE and parC) within the quinolone resistance-determining region revealed that the increase in the MICs of the quinolones had not resulted from any significant mutation. Analysis of genomic DNA from both antimicrobial agent-sensitive and multidrug-resistant serovar Typhi by PFGE identified two distinct subtypes that were in circulation in the three different parts of Kenya. As the prevalence of multidrug-resistant serovar Typhi increases, newer, more expensive, and less readily available antimicrobial agents will be required for the treatment of typhoid in Kenya.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070992      PMCID: PMC387605          DOI: 10.1128/JCM.42.4.1477-1482.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Specific gyrA mutation at codon 83 in nalidixic acid-resistant Salmonella enterica serovar Typhi strains isolated from Vietnamese patients.

Authors:  Le Van Phung; Haruko Ryo; Taisei Nomura
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Nalidixic acid-resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh.

Authors:  S M Zahurul Haque Asna; J Ashraful Haq; Md Mushfequr Rahman
Journal:  Jpn J Infect Dis       Date:  2003-02       Impact factor: 1.362

3.  Multi-drug resistant typhoid: a global problem.

Authors:  S H Mirza; N J Beeching; C A Hart
Journal:  J Med Microbiol       Date:  1996-05       Impact factor: 2.472

4.  Multidrug-resistant strains of Salmonella enterica serotype typhi are genetically homogenous and coexist with antibiotic-sensitive strains as distinct, independent clones.

Authors:  Z A Bhutta; T Pang
Journal:  Int J Infect Dis       Date:  2000       Impact factor: 3.623

5.  DNA sequence analysis of DNA gyrase and DNA topoisomerase IV quinolone resistance-determining regions of Salmonella enterica serovar Typhi and serovar Paratyphi A.

Authors:  Kenji Hirose; Ai Hashimoto; Kazumichi Tamura; Yoshiaki Kawamura; Takayuki Ezaki; Hiroko Sagara; Haruo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

6.  Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom.

Authors:  E J Threlfall; L R Ward
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

7.  Decline in epidemic of multidrug resistant Salmonella typhi is not associated with increased incidence of antibiotic-susceptible strain in Bangladesh.

Authors:  M Rahman; A Ahmad; S Shoma
Journal:  Epidemiol Infect       Date:  2002-08       Impact factor: 2.451

8.  Molecular characterization of antibiotic resistance in clinical Salmonella typhi isolated in Ghana.

Authors:  Felix Mills-Robertson; Marian E Addy; Patience Mensah; Scott S Crupper
Journal:  FEMS Microbiol Lett       Date:  2002-10-08       Impact factor: 2.742

9.  Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India.

Authors:  J C Brown; P M Shanahan; M V Jesudason; C J Thomson; S G Amyes
Journal:  J Antimicrob Chemother       Date:  1996-05       Impact factor: 5.790

10.  Genotypic analysis of multidrug-resistant Salmonella enterica Serovar typhi, Kenya.

Authors:  S Kariuki; C Gilks; G Revathi; C A Hart
Journal:  Emerg Infect Dis       Date:  2000 Nov-Dec       Impact factor: 6.883

View more
  25 in total

1.  Genetic determinants and polymorphisms specific for human-adapted serovars of Salmonella enterica that cause enteric fever.

Authors:  Dobryan M Tracz; Helen Tabor; Morganne Jerome; Lai-King Ng; Matthew W Gilmour
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia.

Authors:  Samuel Kariuki; Gunturu Revathi; John Kiiru; Doris M Mengo; Joyce Mwituria; Jane Muyodi; Agnes Munyalo; Yik Y Teo; Kathryn E Holt; Robert A Kingsley; Gordon Dougan
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

3.  In vitro synergism of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotypes Paratyphi A and Paratyphi B.

Authors:  Ganesh Prasad Neupane; Dong-Min Kim; Sung Hun Kim; Bok Kwon Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

4.  Antimicrobial resistance in Salmonella enterica Serovar Typhi isolates from Bangladesh, Indonesia, Taiwan, and Vietnam.

Authors:  Chien-Shun Chiou; Tsai-Ling Lauderdale; Dac Cam Phung; Haruo Watanabe; Jung-Che Kuo; Pei-Jen Wang; Yen-Yi Liu; Shiu-Yun Liang; Pei-Chen Chen
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

Review 5.  WITHDRAWN: Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever).

Authors:  Emmanuel E Effa; Hasifa Bukirwa
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

6.  Evaluation of the detection of staA, viaB and sopE genes in Salmonella spp. using the polymerase chain reaction (PCR).

Authors:  Francis Kariuki; Pauline Getanda; Atunga Nyachieo; Gerald Juma; Peter Kinyanjui; Joseph Kamau
Journal:  Arch Microbiol       Date:  2021-12-18       Impact factor: 2.552

7.  Emergence of multidrug-resistant Salmonella enterica serotype Typhi with decreased ciprofloxacin susceptibility in Bangladesh.

Authors:  M Rahman; A K Siddique; S Shoma; H Rashid; M A Salam; Q S Ahmed; G B Nair; R F Breiman
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

8.  Salmonella typhi in the democratic republic of the congo: fluoroquinolone decreased susceptibility on the rise.

Authors:  Octavie Lunguya; Veerle Lejon; Marie-France Phoba; Sophie Bertrand; Raymond Vanhoof; Jan Verhaegen; Anthony Marius Smith; Karen Helena Keddy; Jean-Jacques Muyembe-Tamfum; Jan Jacobs
Journal:  PLoS Negl Trop Dis       Date:  2012-11-15

9.  Temporal fluctuation of multidrug resistant salmonella typhi haplotypes in the mekong river delta region of Vietnam.

Authors:  Kathryn E Holt; Christiane Dolecek; Tran Thuy Chau; Pham Thanh Duy; Tran Thi Phi La; Nguyen Van Minh Hoang; Tran Vu Thieu Nga; James I Campbell; Bui Huu Manh; Nguyen Van Vinh Chau; Tran Tinh Hien; Jeremy Farrar; Gordon Dougan; Stephen Baker
Journal:  PLoS Negl Trop Dis       Date:  2011-01-04

10.  Multidrug-resistant Salmonella enterica serovar paratyphi A harbors IncHI1 plasmids similar to those found in serovar typhi.

Authors:  Kathryn E Holt; Nicholas R Thomson; John Wain; Minh Duy Phan; Satheesh Nair; Rumina Hasan; Zulfiqar A Bhutta; Michael A Quail; Halina Norbertczak; Danielle Walker; Gordon Dougan; Julian Parkhill
Journal:  J Bacteriol       Date:  2007-03-23       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.